schliessen

Filtern

 

Bibliotheken

Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis

A parasite-specific 51-kDa protein has been isolated from the membrane of macrophages infected with Leishmania donovani, the causative agent of visceral leishmaniasis. Active targeting of doxorubicin to infected macrophages was studied by incorporating it in immunoliposomes prepared by grafting F(ab... Full description

Journal Title: The Journal of infectious diseases 15 March 2004, Vol.189(6), pp.1024-34
Main Author: Mukherjee, Snigdha
Other Authors: Das, Lopamudra , Kole, Labanyamoy , Karmakar, Sudipan , Datta, Neeta , Das, Pijush K
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-1899 ; PMID: 14999606 Version:1
Link: http://pubmed.gov/14999606
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline14999606
title: Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis
format: Article
creator:
  • Mukherjee, Snigdha
  • Das, Lopamudra
  • Kole, Labanyamoy
  • Karmakar, Sudipan
  • Datta, Neeta
  • Das, Pijush K
subjects:
  • Antibodies, Protozoan -- Immunology
  • Doxorubicin -- Administration & Dosage
  • Leishmaniasis, Visceral -- Drug Therapy
ispartof: The Journal of infectious diseases, 15 March 2004, Vol.189(6), pp.1024-34
description: A parasite-specific 51-kDa protein has been isolated from the membrane of macrophages infected with Leishmania donovani, the causative agent of visceral leishmaniasis. Active targeting of doxorubicin to infected macrophages was studied by incorporating it in immunoliposomes prepared by grafting F(ab)'(2) of anti-51-kDa antibody onto the liposomal surface. In a 45-day mouse model of visceral leishmaniasis, complete elimination of spleen parasite burden was achieved by doxorubicin incorporated in immunoliposome (immunodoxosome) at a dose of 250 microg/kg/day that was given for 4 consecutive days. A similar dose of free and liposomal drug (doxosome) had 45% and 84% parasite suppressive effects, respectively. Immunodoxosome and doxosome were generally less toxic than the free drug, as determined by several clinical parameters of cardiotoxicity and liver toxicity. These results not only indicate the potential of doxorubicin as an effective chemotherapeutic agent but also establish the use of immunoliposomes as drug carrier in the therapy of leishmaniasis.
language: eng
source:
identifier: ISSN: 0022-1899 ; PMID: 14999606 Version:1
fulltext: fulltext
issn:
  • 00221899
  • 0022-1899
url: Link


@attributes
ID690075892
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid14999606
sourceidmedline
recordidTN_medline14999606
sourceformatXML
sourcesystemOther
pqid223909430
galeid115761288
display
typearticle
titleTargeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis
creatorMukherjee, Snigdha ; Das, Lopamudra ; Kole, Labanyamoy ; Karmakar, Sudipan ; Datta, Neeta ; Das, Pijush K
ispartofThe Journal of infectious diseases, 15 March 2004, Vol.189(6), pp.1024-34
identifierISSN: 0022-1899 ; PMID: 14999606 Version:1
subjectAntibodies, Protozoan -- Immunology ; Doxorubicin -- Administration & Dosage ; Leishmaniasis, Visceral -- Drug Therapy
descriptionA parasite-specific 51-kDa protein has been isolated from the membrane of macrophages infected with Leishmania donovani, the causative agent of visceral leishmaniasis. Active targeting of doxorubicin to infected macrophages was studied by incorporating it in immunoliposomes prepared by grafting F(ab)'(2) of anti-51-kDa antibody onto the liposomal surface. In a 45-day mouse model of visceral leishmaniasis, complete elimination of spleen parasite burden was achieved by doxorubicin incorporated in immunoliposome (immunodoxosome) at a dose of 250 microg/kg/day that was given for 4 consecutive days. A similar dose of free and liposomal drug (doxosome) had 45% and 84% parasite suppressive effects, respectively. Immunodoxosome and doxosome were generally less toxic than the free drug, as determined by several clinical parameters of cardiotoxicity and liver toxicity. These results not only indicate the potential of doxorubicin as an effective chemotherapeutic agent but also establish the use of immunoliposomes as drug carrier in the therapy of leishmaniasis.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/14999606$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Mukherjee, Snigdha
1Das, Lopamudra
2Kole, Labanyamoy
3Karmakar, Sudipan
4Datta, Neeta
5Das, Pijush K
titleTargeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis
descriptionA parasite-specific 51-kDa protein has been isolated from the membrane of macrophages infected with Leishmania donovani, the causative agent of visceral leishmaniasis. Active targeting of doxorubicin to infected macrophages was studied by incorporating it in immunoliposomes prepared by grafting F(ab)'(2) of anti-51-kDa antibody onto the liposomal surface. In a 45-day mouse model of visceral leishmaniasis, complete elimination of spleen parasite burden was achieved by doxorubicin incorporated in immunoliposome (immunodoxosome) at a dose of 250 microg/kg/day that was given for 4 consecutive days. A similar dose of free and liposomal drug (doxosome) had 45% and 84% parasite suppressive effects, respectively. Immunodoxosome and doxosome were generally less toxic than the free drug, as determined by several clinical parameters of cardiotoxicity and liver toxicity. These results not only indicate the potential of doxorubicin as an effective chemotherapeutic agent but also establish the use of immunoliposomes as drug carrier in the therapy of leishmaniasis.
subject
0Antibodies, Protozoan -- Immunology
1Doxorubicin -- Administration & Dosage
2Leishmaniasis, Visceral -- Drug Therapy
general
014999606
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline14999606
issn
000221899
10022-1899
rsrctypearticle
creationdate2004
addtitleThe Journal of infectious diseases
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr4120040315
citationpf 1024 vol 189 issue 6
startdate20040315
enddate20040315
lsr30VSR-Enriched:[pqid, doi, eissn, pages, galeid]
sort
titleTargeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis
authorMukherjee, Snigdha ; Das, Lopamudra ; Kole, Labanyamoy ; Karmakar, Sudipan ; Datta, Neeta ; Das, Pijush K
creationdate20040315
lso0120040315
facets
frbrgroupid8579330998078933091
frbrtype5
newrecords20190701
languageeng
creationdate2004
topic
0Antibodies, Protozoan–Immunology
1Doxorubicin–Administration & Dosage
2Leishmaniasis, Visceral–Drug Therapy
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Mukherjee, Snigdha
1Das, Lopamudra
2Kole, Labanyamoy
3Karmakar, Sudipan
4Datta, Neeta
5Das, Pijush K
jtitleJournal Of Infectious Diseases
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Mukherjee
1Das
2Kole
3Karmakar
4Datta
aufirst
0Snigdha
1Lopamudra
2Labanyamoy
3Sudipan
4Neeta
5Pijush K
au
0Mukherjee, Snigdha
1Das, Lopamudra
2Kole, Labanyamoy
3Karmakar, Sudipan
4Datta, Neeta
5Das, Pijush K
atitleTargeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis
jtitleThe Journal of infectious diseases
risdate20040315
volume189
issue6
spage1024
pages1024-1034
issn0022-1899
formatjournal
genrearticle
ristypeJOUR
abstractA parasite-specific 51-kDa protein has been isolated from the membrane of macrophages infected with Leishmania donovani, the causative agent of visceral leishmaniasis. Active targeting of doxorubicin to infected macrophages was studied by incorporating it in immunoliposomes prepared by grafting F(ab)'(2) of anti-51-kDa antibody onto the liposomal surface. In a 45-day mouse model of visceral leishmaniasis, complete elimination of spleen parasite burden was achieved by doxorubicin incorporated in immunoliposome (immunodoxosome) at a dose of 250 microg/kg/day that was given for 4 consecutive days. A similar dose of free and liposomal drug (doxosome) had 45% and 84% parasite suppressive effects, respectively. Immunodoxosome and doxosome were generally less toxic than the free drug, as determined by several clinical parameters of cardiotoxicity and liver toxicity. These results not only indicate the potential of doxorubicin as an effective chemotherapeutic agent but also establish the use of immunoliposomes as drug carrier in the therapy of leishmaniasis.
pmid14999606
doi10.1086/382048
eissn15376613
oafree_for_read
date2004-03-15